Sun Pharma Share Price Target; Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) stands as India’s largest pharmaceutical company and a significant global player in the generics and specialty medicines market. With a robust product portfolio, strategic acquisitions, and a strong presence in over 100 countries, Sun Pharma continues to demonstrate resilience and growth in the ever-evolving pharmaceutical landscape. This article delves into Sun Pharma’s financial performance, shareholding pattern, and projected share price targets from 2025 to 2030.
Sun Pharma Company Overview
| Metric | Details |
|---|---|
| Company Name | Sun Pharmaceutical Industries Ltd. |
| Founded | 1983 |
| Headquarters | Mumbai, Maharashtra, India |
| Industry | Pharmaceuticals |
| Key Products | Specialty & Generic Medications, APIs |
| Market Cap | ₹4,04,900 Crore (as of April 2025) |
| Stock Ticker | NSE: SUNPHARMA |
| 52-Week Range | ₹1,377.20 – ₹1,960.35 |
| Face Value | ₹1 |
| Dividend Yield | 0.80% |
Sun Pharma Financial Performance
Sun Pharma has showcased consistent financial growth over the years. As per the latest financial reports:
- Revenue (FY24): ₹4,84,968.5 Crore
- Net Profit (Q3 FY25): ₹2,903.4 Crore, marking a 15% increase year-over-year
- Return on Equity (ROE): 15.99%
- Earnings Per Share (EPS): ₹47.65
- Debt to Equity Ratio: 0.04, indicating a strong balance sheet
The company’s revenue has been bolstered by strong domestic sales and a growing specialty pharmaceuticals segment. In Q3 FY25, domestic sales rose by 14% to ₹43 billion, while the global specialty segment saw a 17.5% increase, contributing significantly to the overall revenue .
Sun Pharma Shareholding Pattern (as of March 2025)
| Category | Holding (%) |
|---|---|
| Promoters | 54.48% |
| Foreign Institutional Investors (FII) | 17.96% |
| Mutual Funds | 12.21% |
| Retail & Others | 8.92% |
| Domestic Institutional Investors (DII) | 6.31% |
The substantial holding by promoters indicates strong confidence in the company’s future prospects. Notably, the number of FII/FPI investors increased from 1,310 to 1,351 in the March 2025 quarter, reflecting growing international interest .
Sun Pharma Share Price Targets (2025–2030)
Based on technical analysis and market trends, here are the projected share price targets for Sun Pharma:
| Month | Target Price (₹) |
|---|---|
| January | ₹1,600 |
| February | ₹1,630 |
| March | ₹1,640 |
| April | ₹1,680 |
| May | ₹1,705 |
| June | ₹1,735 |
| July | ₹1,760 |
| August | ₹1,785 |
| September | ₹1,810 |
| October | ₹1,835 |
| November | ₹1,870 |
| December | ₹1,900 |
Sun Pharma Yearly Targets
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | ₹1,600 | ₹1,900 |
| 2026 | ₹1,750 | ₹2,400 |
| 2027 | ₹2,100 | ₹2,700 |
| 2028 | ₹2,250 | ₹2,900 |
| 2029 | ₹2,500 | ₹3,200 |
| 2030 | ₹2,750 | ₹3,500 |
These projections are based on positive market trends and the company’s consistent performance .
Sun Pharma Growth Drivers
- Specialty Pharmaceuticals Expansion: The company’s focus on high-margin specialty drugs, including treatments for psoriasis and alopecia, has led to significant revenue growth in this segment.
- Strong Domestic Market: Sun Pharma holds an 8.5% market share in the ₹1,970 billion Indian pharmaceutical market, ranking No. 1 as per AIOCD AWACS MAT Mar-2024 report .
- Global Presence: With operations in over 100 countries, the company benefits from diversified revenue streams and reduced dependency on any single market.
- Robust R&D Pipeline: Continuous investment in research and development ensures a steady flow of new and innovative products.
Sun Pharma Risks and Challenges
- Regulatory Hurdles: Compliance with international regulatory standards is crucial. Any lapses can lead to product recalls or bans.
- Market Competition: The pharmaceutical industry is highly competitive, with pressure on pricing and market share.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a financial advisor before making investment decisions.
